What OATS offers that microfracture does not

If microfracture is a day-case procedure and OATS is more involved, why would a surgeon recommend OATS? The short answer is tissue quality — and what happens to that tissue once you return to sport.

Microfracture works by puncturing the bone beneath a cartilage defect to release marrow cells, which then form a repair patch. That patch is fibrocartilage — a scar-like tissue that is mechanically weaker than the hyaline cartilage that originally lined the joint. Under the repetitive pivoting and impact loads of sport, fibrocartilage tends to soften and break down. The problem is that this process takes time: most patients feel reasonably well at six to twelve months, which can give an encouraging early picture that does not reflect what the tissue is doing.

OATS — osteochondral autograft transfer — takes a different approach. Cylindrical plugs of genuine hyaline cartilage, complete with the underlying subchondral bone architecture, are harvested from a lower-demand area of the same knee and press-fitted into the defect. The result is structurally and biologically closer to the original tissue.

The clinical consequence of this difference rarely shows at six months. Evidence suggests the divergence between the two procedures becomes apparent beyond two to three years — precisely the timeframe at which many active patients expect to be back to full training and competition.

What a decade of follow-up data shows

The strongest single dataset comes from Gudas and colleagues, who conducted the only prospective randomised controlled trial designed exclusively for young athletes and followed patients to a genuine ten-year endpoint. Treatment failure occurred in 14% of the osteochondral autograft group versus 38% of the microfracture group (P<0.05) — a gap that held when the cohort was extended to fifteen to seventeen years.

Solheim's 2018 comparative cohort (84 OAT patients, 119 microfracture patients) adds a time-resolved picture. Mean time to failure was 8.4 years for OAT versus 4.0 years for microfracture (P=0.01). The Kaplan-Meier survival curves tell the story clearly: OAT remained above 80% survival through year seven and above 60% at year fifteen, while microfracture fell below the 80% threshold within the first twelve post-operative months — before most athletes have returned to competitive training.

At the procedural level, a 2024 institutional registry of 63 mosaicplasty patients (mean age 27.4 years, mean lesion 2.3 cm²) confirms this durability in practice. IKDC scores improved from 46.4 to 70.4 at ten-year follow-up, and only two patients (3.2%) required conversion to arthroplasty.

One important qualification: a 2026 BMJ Open systematic review found that RCT-level evidence for superiority in patient-reported symptom scores carries only low certainty. Survival rates and failure rates are robustly supported; whether OAT patients report meaningfully better symptoms than microfracture patients at every time point is less firmly established.

For context, short-term return-to-play figures for microfracture in elite athletes can appear reassuring — one series reported 94% returning at a mean of 9.3 months. But only 54.5% of those with five-year follow-up were still competing, and athletes with lesions larger than 2 cm in diameter showed significantly worse outcomes at both two and five years. The gap between procedures widens, not narrows, as follow-up extends.

Why microfracture fails under athletic loading

Microfracture drilling does not just fail to regenerate durable cartilage — it disrupts the subchondral bone plate, the structural foundation on which any subsequent repair must rest. This has a practical consequence: a knee that has undergone microfracture is not at the same starting point for revision as one that has not, and several biological alternatives carry a higher failure rate when prior marrow-stimulation has altered the subchondral architecture.

The early picture after microfracture can be deceptive. Fibrocartilage fill does provide genuine symptomatic relief — hence the high short-term return-to-play rates noted in the previous section — but the tissue has inferior stiffness and compressive resistance compared with hyaline cartilage. Under the sustained pivoting and impact forces of sport, it softens progressively. The two-to-three-year window before clinical deterioration reflects not arbitrary timing but the rate at which that degradation accumulates under load.

Certain findings at assessment predict this trajectory reliably. Lesions exceeding 1.5–2 cm², multiple defects, lateral meniscal involvement, and post-operative joint effusion on return to sport are each independently associated with failure to be competing at five years. In a series of 56 elite athletes, each factor significantly worsened long-term outcomes. These are the same clinical and imaging features that most consistently favour OATS over microfracture — the prognostic overlap is not coincidental; it reflects the mechanical reality that larger and more complex lesions generate precisely the loading conditions fibrocartilage cannot sustain.

Microfracture had a practical role when more technically demanding options were less widely available. For active patients whose scan shows any of these features, it is no longer the appropriate first choice.

Who is a candidate for OATS

The typical candidate for OATS is an active adult under 50 with a focal, full-thickness chondral or osteochondral defect — ICRS grade III or IV on imaging or arthroscopy — in a weight-bearing zone of the knee.

Defect size is the most practical filter. The operative window for autograft transfer runs from approximately 1 cm² up to 4 cm² (roughly 20–25 mm in diameter). Above that threshold, the volume of graft required from a low-demand harvest site on the same knee creates unacceptable donor-site morbidity; in those cases, osteochondral allograft transplantation or cell-based repair such as MACI becomes more appropriate.

Location shapes both the diagnosis and the surgical plan. In the largest systematic review of 1,139 patients, the medial femoral condyle accounted for 75.4% of treated sites — it is both the most commonly affected weight-bearing surface and the most consistently accessible for plug harvest and stable press-fit seating. The lateral femoral condyle is also routinely treated. Patellar and trochlear defects can be addressed, but require an open rather than arthroscopic approach, with correspondingly larger mean defect sizes handled.

Exclusions are equally important. OATS is contraindicated in diffuse osteoarthritis, inflammatory arthropathy, and knees where a previous cartilage procedure — particularly prior marrow-stimulation — has already disrupted the subchondral bone plate. Alignment and ligament integrity are assessed at consultation; significant malalignment or instability is usually corrected either in advance or concurrently.

For patients whose imaging and clinical assessment reveal the prognostic features described in the previous section — those that predict poor long-term outcomes after microfracture — OATS warrants consideration even when the defect might nominally sit within the historical microfracture size range. Suitability ultimately rests on a full consultant review rather than any single parameter in isolation.

How defect size and location shape the decision

Size thresholds form the clearest organising principle here. At the smaller end — defects below roughly 1 cm² — marrow-stimulation techniques such as microfracture or single-stage AMIC may be adequate; harvesting autograft plugs for a defect of that scale introduces donor-site risk disproportionate to any incremental gain. The autograft window opens above that point and runs to approximately 4 cm². Mosaicplasty — transferring several smaller plugs rather than one large core — extends workable coverage through the upper part of that range; the 63-patient institutional cohort discussed in section two treated a mean lesion of 2.3 cm² across an average of 2.2 plugs, confirming durability at that scale. Above 4 cm², the volume of graft required from a low-demand harvest site risks meaningful morbidity, and the clinical balance shifts toward osteochondral allograft (OCA) or cell-based repair such as ACI or MACI — covered in the next section.

Location adds nuance

Arthroscopic OAT suits smaller condylar defects, averaging around 1 cm² in published series; the open approach reaches the patella and trochlea, handling defects averaging nearly 3 cm², though complication rates are modestly higher (39 events in 279 open-approach patients versus 14 in 594 arthroscopic) even while functional scores remain comparable between routes.

Evidence depth varies considerably by site. The medial femoral condyle is well-represented across series totalling more than a thousand patients, and outcome data there are robust. The lateral condyle and trochlea each account for smaller subgroups — 12.1% and 5.7% of cases respectively in the 1,139-patient systematic review — so outcome estimates at those sites carry wider uncertainty and individual cases are harder to benchmark against published figures. That gap is an area of ongoing evidence development rather than a contraindication, but it is relevant to realistic expectations at consultation.

A further variable is lesion depth. Where damage extends into subchondral bone, the full osteochondral unit must be restored rather than the cartilage surface alone. MRI review and consultant assessment are needed to confirm this before a surgical approach is decided.

OATS alongside other cartilage repair options

Against biological alternatives, OATS occupies a specific niche rather than a universal one.

For the focal sub-4 cm² condylar defect in a patient under 50 returning to load-bearing sport, OATS holds its strongest evidence — the Gudas trial figures and Solheim survival data already described apply to precisely this profile. ACI and MACI are established alternatives, but both are two-stage procedures: a cartilage biopsy is taken at a first operation, cells are cultured over several weeks, and the implant placed at a second. Their established indication starts at around 2 cm² and extends to 10 cm², overlapping with the upper autograft window, though head-to-head comparison with OATS for the smaller focal defect is not reliably established in the published literature.

Return-to-sport rates after ACI illustrate this uncertainty. Across 16 published series included in one scoping review, ACI figures ranged from 33% to 96% — a spread that reflects heterogeneous patient populations and inconsistent reporting rather than a coherent picture of technique performance. The equivalent range for OATS in pivoting-sport athletes was 87–100%.

For defects above 4 cm², osteochondral allograft (OCA) transplantation is the appropriate escalation — using donor tissue rather than a harvest site on the same knee, with long-term follow-up series supporting its durability in larger posttraumatic defects.

Where the evidence remains thin

Two gaps are worth naming directly. The 2024 professional-athlete meta-analysis of 476 patients found 96.6% were male, making precise outcome predictions for female athletes provisional at best. Separately, over 54% of return-to-sport studies across cartilage techniques omitted lesion size or location — limiting reliable benchmarking for lateral condyle, trochlear, and patellar defects in particular.

The clinical signal is most settled for focal condylar defects above roughly 1 cm² in patients under 50 who plan to return to pivoting or load-bearing sport. For other anatomical sites and across female athletic populations, it remains an area of active evidence development — something a thorough consultant assessment, drawing on individual imaging and activity profile, is best placed to address.

1. [1] Factors Affecting Return to Sport in Elite Athletes After Microfracture for Chondral Lesions in the Knee. (2023). https://doi.org/10.1302/1358-992x.2023.13.073 https://doi.org/10.1302/1358-992x.2023.13.073
2. [2] Microfracture for full-thickness chondral lesions of the knee in elite athletes leads to high return-to-play rates. (2025). https://doi.org/10.1002/ksa.12808 https://doi.org/10.1002/ksa.12808
3. [3] Mosaicplasty/Osteochondral Autograft Transfer Remains a Durable Solution for Symptomatic Chondral Defects of the Knee: Two to Ten-Year Follow-up Analysis. (2024). https://doi.org/10.1177/2325967124s00003 https://doi.org/10.1177/2325967124s00003
4. [4] Return to Sport in Professional Athletes After Cartilage Restoration Surgery of the Knee: A Systematic Review and Meta-Analysis. (2024). https://doi.org/10.1177/19476035241292793 https://doi.org/10.1177/19476035241292793
5. [5] Arthroscopic versus Open Osteochondral Autograft Transplantation (Mosaicplasty) for Cartilage Damage of the Knee: A Systematic Review. (2019). https://doi.org/10.1055/s-0039-1692999 https://doi.org/10.1055/s-0039-1692999
6. [6] A cross-sport comparison of performance-based outcomes of professional athletes following primary microfracture of the knee. (2018). https://doi.org/10.1016/j.knee.2018.04.008 https://doi.org/10.1016/j.knee.2018.04.008